Last update 12 Dec 2024
Prolgolimab/nurulimab
Last update 12 Dec 2024
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms BCD 217 |
Target |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 143797L
The sequence is quoted from: *****
Sequence Code 317913292L
The sequence is quoted from: *****
Sequence Code 616723098H
The sequence is quoted from: *****
Sequence Code 616724483H
The sequence is quoted from: *****
Related
3
Clinical Trials associated with Prolgolimab/nurulimabA Randomized Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma.
A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
International Multicenter Double-Blind Placebo-Controlled Comparative Randomized Trial of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) And BCD-100 (Anti-PD-1) Therapy Compared to BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma
100 Clinical Results associated with Prolgolimab/nurulimab
Login to view more data
100 Translational Medicine associated with Prolgolimab/nurulimab
Login to view more data
100 Patents (Medical) associated with Prolgolimab/nurulimab
Login to view more data
100 Deals associated with Prolgolimab/nurulimab
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Malignant melanoma, metastatic | Phase 3 | BY | 02 Aug 2022 | |
| Malignant melanoma, metastatic | Phase 3 | IN | 02 Aug 2022 | |
| Malignant melanoma, metastatic | Phase 3 | RU | 02 Aug 2022 | |
| Melanoma, Cutaneous Malignant | Phase 3 | BY | 02 Aug 2022 | |
| Melanoma, Cutaneous Malignant | Phase 3 | IN | 02 Aug 2022 | |
| Melanoma, Cutaneous Malignant | Phase 3 | RU | 02 Aug 2022 | |
| Unresectable Melanoma | Phase 3 | BY | 02 Aug 2022 | |
| Unresectable Melanoma | Phase 3 | IN | 02 Aug 2022 | |
| Unresectable Melanoma | Phase 3 | RU | 02 Aug 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | Melanoma Neoadjuvant | 57 | ndubmyjaur(qfzxqsjghs) = jprligkhxy iwtnsyaqgi (uohuumkmlr ) View more | Positive | 14 Sep 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free